Summary:
This study will evaluate the safety and effectiveness of an investigational medication in reducing high levels of eosinophils in the blood and in the tissue of the digestive tract, and improving symptoms in people with EG and/or EGE.
Qualified Participants Must:
• Ages 18-80 years old
•
Experience Eosinophilic Gastritis (EG) and/or Eosinophilic Gastroenteritis (EGE), or Eosinophilic Esophagitis (EoE) with gastric symptoms
Qualified Participants May Receive:
There is no cost to participate in this study. Qualified participants will receive study-related drugs, lab tests, and study-related medical care at no cost. You will also be eligible for compensation to cover the cost of your time and travel. Your participation may help evaluate a potential treatment for these debilitating diseases.